DXRX — Diaceutics Income Statement
0.000.00%
Last trade - 00:00
- £88.08m
- £71.46m
- £19.50m
- 82
- 22
- 80
- 69
2018 December 31st | 2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10.4 | 13.4 | 12.7 | 13.9 | 19.5 |
Cost of Revenue | |||||
Gross Profit | 6.8 | 10.3 | 9.46 | 12.2 | 16.7 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.17 | 12.7 | 13.4 | 13.4 | 18.9 |
Operating Profit | 1.2 | 0.74 | -0.658 | 0.55 | 0.575 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.877 | 0.497 | -0.682 | 0.462 | 0.564 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.632 | 0.398 | 0.263 | 0.561 | 0.724 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.632 | 0.398 | 0.263 | 0.561 | 0.724 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.632 | 0.398 | 0.263 | 0.561 | 0.724 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.011 | 0.023 | 0.007 | 0.007 | 0.008 |
Dividends per Share |